Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Leeder

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Clinical Pharmacology and Therapeutics|December 15, 2015
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHDJ T Brown, S M Abdel-Rahman, L van Haandel, et al.
Clinical Pharmacology and Therapeutics|August 23, 2008
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyP Madadi, C J D Ross, M R Hayden, et al.
Pharmacogenetics|April 26, 2000
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activityA D Kashuba, A N Nafziger, G L Kearns, et al.
Analytical Biochemistry|November 1, 1987
One-step enzyme immunochromatographic assay for theophyllineT M Li, R Chen, S Leeder, et al.
Clinical Pharmacology and Therapeutics|June 19, 1998
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotypingA D Kashuba, J S Bertino, G L Kearns, et al.
Pediatric Obesity|September 27, 2018
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesityV Shakhnovich, S Abdel-Rahman, C A Friesen, et al.
Pharmacogenetics and Genomics|February 21, 2012
Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variabilityMara L Becker, Leon van Haandel, Roger Gaedigk, et al.
Pharmacogenetics|November 24, 1998
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotypingA D Kashuba, A N Nafziger, G L Kearns, et al.
Clinical Pharmacology and Therapeutics|December 1, 1999
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotypingD S Streetman, R E Ellis, A N Nafziger, et al.
Clinical Pharmacology and Therapeutics|March 30, 2007
Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotypeA Gaedigk, J D Eklund, R E Pearce, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Clinical Pharmacology and Therapeutics|December 15, 2015
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHDJ T Brown, S M Abdel-Rahman, L van Haandel, et al.
Clinical Pharmacology and Therapeutics|August 23, 2008
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyP Madadi, C J D Ross, M R Hayden, et al.
Pharmacogenetics|April 26, 2000
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activityA D Kashuba, A N Nafziger, G L Kearns, et al.
Analytical Biochemistry|November 1, 1987
One-step enzyme immunochromatographic assay for theophyllineT M Li, R Chen, S Leeder, et al.
Clinical Pharmacology and Therapeutics|June 19, 1998
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotypingA D Kashuba, J S Bertino, G L Kearns, et al.
Pediatric Obesity|September 27, 2018
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesityV Shakhnovich, S Abdel-Rahman, C A Friesen, et al.
Pharmacogenetics and Genomics|February 21, 2012
Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variabilityMara L Becker, Leon van Haandel, Roger Gaedigk, et al.
Pharmacogenetics|November 24, 1998
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotypingA D Kashuba, A N Nafziger, G L Kearns, et al.
Clinical Pharmacology and Therapeutics|December 1, 1999
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotypingD S Streetman, R E Ellis, A N Nafziger, et al.
Clinical Pharmacology and Therapeutics|March 30, 2007
Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotypeA Gaedigk, J D Eklund, R E Pearce, et al.
Pageof 13